Mutual Fund Series Trust has filed a summary prospectus for its Eventide Healthcare & Life Sciences Fund, which aims to achieve long-term capital appreciation. This filing, dated November 4, 2026, is significant as it provides potential investors with detailed information about the fund's objectives and associated fees.

As a company incorporated in Ohio, Mutual Fund Series Trust operates within the investment sector. The firm has a history of providing various mutual fund options, with the Eventide Healthcare & Life Sciences Fund being one of its key offerings. The fund focuses on investments in the healthcare and life sciences sector, which has seen growing interest among investors due to its potential for robust returns.

The filing states, "The Eventide Healthcare & Life Sciences Fund seeks to achieve long-term capital appreciation." This statement underscores the fund's strategic focus on growth within a vital industry. Additionally, the prospectus outlines various fees and expenses that investors may incur, including management fees and sales charges, crucial for potential investors to consider.

This update may affect both individual investors and financial intermediaries who offer shares of the fund. Investors will benefit from enhanced transparency regarding fees and investment strategies, allowing for more informed decision-making. Financial intermediaries may also need to adjust their offerings or fee structures to remain competitive in light of this increased transparency.

The filing does not specify what actions will follow this update, leaving the next steps open-ended for both the company and its investors.